98%
921
2 minutes
20
Background: Variability exists in sertraline pharmacokinetic parameters in individuals, especially obvious in adolescents. We aimed to establish an individualized dosing model of sertraline for adolescents with depression based on artificial intelligence (AI) techniques.
Methods: Data were collected from 258 adolescent patients treated at the First Hospital of Hebei Medical University between December 2019 to July 2022. Nine different algorithms were used for modeling to compare the prediction abilities on sertraline daily dose, including XGBoost, LGBM, CatBoost, GBDT, SVM, ANN, TabNet, KNN, and DT. Performance of four dose subgroups (50 mg, 100 mg, 150 mg, and 200 mg) were analyzed.
Results: CatBoost was chosen to establish the individualized medication model with the best performance. Six important variables were found to be correlated with sertraline dose, including plasma concentration, PLT, MPV, GL, A/G, and LDH. The ROC curve and confusion matrix exhibited the good prediction performance of CatBoost model in four dose subgroups (the AUC of 50 mg, 100 mg, 150 mg, and 200 mg were 0.93, 0.81, 0.93, and 0.93, respectively).
Conclusion: The AI-based dose prediction model of sertraline in adolescents with depression had a good prediction ability, which provides guidance for clinicians to propose the optimal medication regimen.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/17512433.2024.2304009 | DOI Listing |
Neuropsychopharmacology
September 2025
Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
This report sought to employ multi-modal integration of pre-treatment brain (electroencephalogram, resting-state functional magnetic resonance imaging) and blood (immune and metabolic) biomarkers to facilitate causal inference-based treatment selection by virtue of establishing predictability of remission to multi-stage antidepressant treatment. Data from two stages of pharmacotherapy in the 'Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression' (EMBARC) study from participants with both brain and blood biomarkers were included (N = 197). Participants were initially randomized to sertraline or placebo (Stage 1), and depending on clinical response at week-8, their therapy in Stage 2 was either maintained or switched (to sertraline, if a non-responder to placebo, or to bupropion, if a non-responder to sertraline).
View Article and Find Full Text PDFJACC Clin Electrophysiol
September 2025
Department of Cardiovascular Diseases, Division of Heart Rhythm Services, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, Minnesota, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Ro
Background: Long QT syndrome (LQTS) is a potentially life-threatening genetic heart disease. Because many psychiatric medications have QT-prolonging potential, there is hesitation when prescribing them to LQTS patients with concomitant psychiatric disorders, which may lead to suboptimal mental health care.
Objectives: This study sought to evaluate the incidence of breakthrough cardiac events (BCEs) in patients with diagnosed and clinically treated LQTS on QT-prolonging psychiatric medications.
J Affect Disord
September 2025
Department of Traditional Chinese Medicine, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, China. Electronic address:
Introduction: Dysfunction in amygdala networks has been implicated in major depressive disorder (MDD). Pharmacological treatments, such as esketamine and sertraline, are believed to exert their antidepressant effects by modulating amygdalar activity. This study aimed to investigate the relationship between changes in dynamic functional connectivity (dFC) within amygdala subregions and treatment outcomes, with a focus on identifying potential neuroimaging markers.
View Article and Find Full Text PDFCureus
August 2025
General Internal Medicine and Nephrology, Robert Bosch Krankenhaus, Stuttgart, DEU.
Tubulointerstitial nephritis and uveitis (TINU) syndrome is a rare autoimmune condition primarily affecting adolescents. Diagnosis is frequently delayed due to the nonspecific and temporally dissociated presentation of renal and ocular symptoms. We report the case of a 15-year-old girl who presented to her general practitioner with fatigue, polyuria, and recent weight loss.
View Article and Find Full Text PDFPharmaceutics
July 2025
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Wuerzburg, 97080 Wuerzburg, Germany.
Sex-specific differences in psychopharmacological treatment have gained increasing attention in adults, with studies showing that women often have higher serum concentrations of psychotropic drugs due to biological differences. However, despite recognition of these differences in adults, reference ranges for therapeutic drug monitoring (TDM) in general, but even more sex-specific therapeutic windows for psychotropic drugs, are lacking in children and adolescents, who may metabolize and respond to medications differently. The study aimed to investigate sex-specific differences in antidepressant (AD) and antipsychotic (AP) -treatment outcomes, and pharmacokinetics in childhood/adolescence.
View Article and Find Full Text PDF